Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in achieving clinical remission in patients with moderately to severely active ulcerative colitis (UC), according to results from a phase 3b head-to-head trial.
Peppermint oil (PO) was found to be safe and effective in treating pain and global symptoms associated with irritable bowel syndrome (IBS) in adult patients, according to the results of a recently published systematic review and meta-analysis.
In older patients with inflammatory bowel disease (IBD), tumor necrosis factor alpha antagonist (anti-TNF) therapy and vedolizumab (an integrin receptor antagonist) were found to be comparable with regard to both safety and effectiveness, according to a study published in Alimentary Pharmacology & Therapeutics.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to seladelpar (CymaBay Therapeutics) for the treatment of early-stage primary biliary cholangitis (PBC).
The Food and Drug Administration (FDA) has granted Fast Track designation to RDD-0315, a novel topical gel for the treatment of fecal incontinence in spinal cord injury patients.
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
A recently published report describes the case of a 59-year-old male patient who experienced olmesartan-associated enteropathy (OAE) and highlights the importance of performing thorough medication reviews.
Finch Therapeutics announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
DocuSol Kids has been made available by Alliance Labs for the over-the-counter (OTC) treatment of general constipation in children 2–12 years of age. Each DocuSol Kids mini-enema (5mL) contains a delivered dose of docusate sodium 100mg in a polyethylene glycol base. The soft flexible tip allows for easy rectal usage under adult supervision. According to…
Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus.
